Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
复制标题
DOI：
10.1038/sj.bjc.6600956
复制
发表时间：
2003-06-02
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
转移性乳腺癌患者的生存预测通常不准确，新的生物学参数可能会有所帮助。肿瘤生长依赖于血管生成，因此假设血管生成因子产生的评估可能反映癌症进展的临床行为。本研究旨在探讨血管内皮生长因子（VEGF）和白细胞介素6（IL-6）在激素难治性转移性乳腺癌中的临床意义。使用酶联免疫测定法测量了 87 名有完整记录的转移性乳腺癌病史的患者的血清和血浆 VEGF 浓度以及 IL-6 血清浓度。所有患者均检测到 VEGF 水平，而 39% 的患者血清中检测到 IL-6 水平。 IL-6水平与血小板理论VEGF载量呈正相关（P<0.001）。高水平血清 IL-6（而非 VEGF）的存在与较短的生存期显着相关。在与临床预后参数一起的多变量分析中，血清 IL-6 被确定为总生存期的独立不良预后变量（P<0.001）。这些结果表明，血清 IL-6 水平与激素难治性转移性乳腺癌患者的较差生存率相关。血管内皮生长因子血清和血浆水平并不是这些患者预后的有用指标。
Prediction of survival for patients with metastatic breast cancer is often inaccurate and may be helped by new biological parameters. Tumour growth being angiogenesis-dependent, it has been hypothesised that the assessment of angiogenic factor production might reflect the clinical behaviour of cancer progression. This study was designed to investigate the clinical significance of vascular endothelial growth factor (VEGF) and interleukin 6 (IL-6) in hormone-refractory metastatic breast cancer. Serum and plasma concentrations of VEGF and serum concentration of IL-6 were measured in 87 patients with a fully documented history of metastatic breast cancer using an enzyme-linked immunoassay. All patients had detectable levels of VEGF, whereas 39% patients had detectable serum levels of IL-6. There was a positive correlation between IL-6 levels and the theoretical VEGF load of platelets (P<0.001). The presence of high levels of serum IL-6, but not VEGF, was significantly correlated to a shorter survival. In a multivariate analysis along with clinical prognostic parameters, serum IL-6 was identified as an independent adverse prognostic variable for overall survival (P<0.001). These results indicate that serum IL-6 levels correlate to poor survival in patients with hormone-refractory metastatic breast cancer. Vascular endothelial growth factor serum and plasma levels are not useful indicators of prognosis for these patients.
登录
查看更多内容
影响因子：
8.8
作者：
Manders, P;Beex, LVAM;Sweep, CGJ
通讯作者：
Sweep, CGJ
影响因子：
20.3
作者：
Menetrier-Caux, C;Montmain, G;Blay, JY
通讯作者：
Blay, JY
影响因子：
8.8
作者：
Molica, S;Vitelli, G;Digiesi, G
通讯作者：
Digiesi, G
影响因子：
7.8
作者：
LU, C;KERBEL, RS
通讯作者：
KERBEL, RS
DOI：
10.1073/pnas.94.17.9349
发表时间：
1997-08-19
影响因子：
11.1
作者：
Lotem, J;Sachs, L
通讯作者：
Sachs, L